Recommended

GSK appoints new CEO
New webinar | Addressing the time-to-result challenge posed by short shelf-life radiopharmaceuticals, register today
Genmab acquires biotech Merus for $8bn
US FDA licensing first for IL-23 inhibitor to treat paediatric psoriasis
Teva makes progress on API business divestment
Takeda to move away from cell therapy
news

Growing role of personalised and precision medicine in cancer treatments

11
SHARES

The role of personalised and precision medicine may be ideal for the treatment of cancer, but questions about consequences and society issues still remain…

various different medicines in different forms and containers

Researchers at Rutgers University Department of Biomedicine Engineering have published a recent review paper on the transformative potential of precision and personalised medicine (PPM) for cancer treatment.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The research team included a group of Rutgers PhD fellows and other faculty staff, and considered the entire process from acquiring precision and personalised medicinedata , to developing precision and personalised medicine products. The team of researchers also addressed the broader economic and societal consequences of personalised and precision medicine.

The primary message of the paper, which is a culmination of a cohort of twelve PhD fellows, is that precision and personalised medicine has the potential to transform cancer treatments and therapies. 

With the traditional method focusing on tumor detection, followed by general treatment procedures such as surgery, chemotherapy, and radiation, the research team proposed a precision and personalised medicine approach that could allow for targeted treatments. The aim would be that these treatments are more effective and avoid the side effects that come along with traditional treatments.

The team, from Rutgers University, were funded by the US Department of Education Graduate Training in Emerging Areas of Precision and Personalised Medicine Grant (Award Number P200A150131). Professor Martin Yarmush served as the Program Director and Principal Investigator of the award.

This culminating achievement of twelve PhD fellows looked at treatments that analysed specific tissues, gene mutations, and personal factors relevant to each unique case of cancer, and also addressed societal issues of PPM in healthcare. Despite the fact that it could transform lives, before personalised and precision medicine can be made available many difficult questions would need to be addressed, including feasibility, economic concerns, regulatory challenges, socioeconomic issues and even areas relating to privacy. 

The technology needed for this therapy does currently exist and is rapidly becoming more efficient and sophisticated; however, these questions must be tackled in order to allow for the smooth integration of precision and personalised medicine into cancer care.

The research team published the paper in the journal TECHNOLOGY.

Share via
Share via